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ABSTRACT 
Examination of genomic and proteomic changes associated with ras-driven epithelial 
to mesenchymal transformation (EMT) of polarized epithelial cells has led to an 
improved understanding of surface-expressed structures and alterations in components 
involved in intracellular trafficking events that are altered as normal cells become 
cancerous. We have identified a mechanism involved in the establishment of cell-cell 
contracts known as tight junctions (TJs) which involves the orchestrating actions of 
the protein occludin (Ocln) and its ability to reverse EMT events. A screen for agents 
to re-activate suppressed occludin (OCLN) gene function caused by Ras/Raf/MEK/ERK 
pathway activation has led to the identification of several small molecules that can 
reverse cellular changes associated with EMT. Additionally, we had previously 
observed the up-regulation of a cell-surface expressed import system for small 
peptides, hPepT1, in pancreatic cancer cells which are known to be to be driven by 
the Ras/Raf/MEK/ERK pathway. We now describe two approaches to identify agents 
capable of re-activating Ocln expression which could be modified to be selectively 
absorbed by cancer cells which over-express functional hPepT1. Using this combined 
information of a drug that functions only in cancer cells having reduced Ocln 
expression with an up-regulated uptake mechanism that correlates reduced Ocln 
expression, we believe that it is possible to identify improved cancer chemotherapies 
that have reduced off-target drug distribution and thus great functional targeting.   
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INTRODUCTION 
While the actual basis for metastasis is currently unclear (1), the impact of this event 
is clear: the majority of cancer-related deaths, up to 90%, can be attributed to 
disseminated disease rather than the impact of the primary tumor 
(http://www.cancerquest.org/metastasis-overview.html). At least half of the patients 
diagnosed with cancer present with clinically detectable metastatic disease (2). For 
these reasons, metastasis is considered the most life-threatening event in patients 
with cancer (3). Thus, strategies to selectively target disseminated disease have 
become a primary focus of drug delivery efforts. A standard approach to target these 
disseminated cancer cells is to use an agent that selectively targets to cancer cells to 
deliver a toxic payload; primarily antibodies that recognize a cancer-associated 
structure. It is clear, however, that previous efforts to selectively target cancer cells 
following systemic administration for the focused delivery of therapeutic agents have 
resulted in only a small fraction of these materials reaching metastatic sites (4). These 
approaches, while delivering measurable amounts of potent cytotoxic agents to 
intended sites typically result in substantial exposure of these agents to non-cancerous 
tissues as well.  
Epithelial to mesenchymal transformation (EMT) is a reversible event, and that 
reversion is known as mesenchymal to epithelial transformation (MET). We have 
examined an underlying cellular pathway known to control endogenous mechanisms 
used by epithelial cells to transition between differentiated and mesenchymal formats 
in wound repair, replacement of senescent cells, etc (5). Importantly, the 
Ras/Raf/MEK/ERK pathway selected for our studies not only functions in reversible 
EMT↔MET process but has also been shown to drive oncogenic conversion following its 
un-regulated activation (6). We have taken the approach that epithelial cancers are a 
manifestation of cells driven into EMT, but that, for a variety of reasons, fail to 
transition back through MET into differentiated epithelial cells.  Further, cellular 
events that “lock” epithelial cells in an oncogenic state might be reversible if the 
correct cellular “key’ was identified. The approach taken in this report describes 
efforts made to find such a “key” and the equally important issue of finding a means 
to allow that key to efficiently find the “lock” in an oncogenic epithelial cell. We 
believe that this concerted approach could lead to novel strategies to selectively 
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modify cancer cell function, allowing for less cytotoxic methods to control these 
aberrant cells.   
The first step to explore this strategy was to identify a cell-specific target that was 
critical in the reversible EMT↔MET processes that are also known to be un-regulated 
in epithelial cancers. It is critical that the EMT↔MET pathway process is understood 
sufficiently to allow transition of oncogenic epithelial cells back into a differentiated 
format. We had previously observed that epithelial cells driven to an oncogenic state 
by constitutively active Raf will down-regulate proteins involved in cell-cell 
interactions that function to signal the presence of and interaction with an adjacent 
epithelial cell. While most proteins involved in these cell-cell contacts were 
suppressed at the protein expression level, only one was observed in our model to be 
affected at the message level: occludin (Ocln). The significance of this observation is 
supported by studies showing that reduced levels of Ocln expression correlated with 
increased cancer progression (7-9). Importantly, forced expression of Ocln protein in 
the presence of continued expression of activated Raf could reverse the oncogenic 
phenotype and retrieve a functional epithelial cell (10).  
Since that initial demonstration, much has been learned about the Raf/Ocln dynamic 
and the role played by Ocln as a counter-balance to the Ras/Raf/MEK/ERK pathway. 
Suppression of the Ras/Raf/MEK/ERK pathway can restore differentiated phenotype 
and functional TJs in a variety of cells types including  transformed canine kidney cells 
(11), human corneal cells (12), mouse hepatocytes (13), and medullary thyroid 
carcinoma cells (14). Epigenetic silencing of OCLN promotes tumorigenic and 
metastatic properties of cancer cells involving and re-activation of endogenous Ocln 
expression makes these cells more susceptible to the induction of apoptosis (15). 
Further, Ocln functions to control premature senescence events; its forced expression 
in breast cancer cells induces anoikis and promotes senescence following oxidative 
stress (16). Overall, these observations support the possibility that inducing Ocln re-
expression in cancer cells could lead to increased sensitivity of these cells to agents 
that could induce cell death via apoptosis and/or senescence pathways (15, 16), 
leading to a more focused and less toxic therapeutic approach.  
The second aspect of our approach requires the identification of a specific target in 
cancer cells that can be selectively “unlocked” using some pharmacological agent. In 
our case, we looked for a means to re-activate Ocln expression. Previous studies have 
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shown that Hela cells treated with retinoic acid receptor α (RARα) agonists or treated 
with a de-methylating agent followed by a histone deacetylase inhibitor can re-express 
endogenous Ocln (16). Due to the broad effects produced by activation of RARα-
mediated pathways or non-specific de-methylation agents, we have instead attempted 
to identify OCLN expression elements specifically regulated by Ras/Raf/MEK/ERK 
pathway activation. This pathway inactivates Ocln at the message level through the 
actions of the suppressor element Slug which interacts with a specific E-box sequence 
within the OCLN promoter; selective suppression of Slug being able to rectify Ocln 
expression suppressed by activated Raf (17). Thus, rectification of Ocln protein 
expression in cancer cells might be achieved by selective disruption of Slug function, a 
suppressor whose increased expression has been associated with epithelial cancers 
(18).  
While chemotherapeutics are typically selected for their ability to enter all cells non-
selectively, the final aspect of our strategy to identify a method that might be used to 
selectively deliver molecules that could affect Slug function to Ras/Raf/MEK/ERK 
pathway activated cancer cells. While re-activation of Ocln expression by Slug-
mediated suppression should have little impact in differentiated epithelial cells with 
function TJ structures or non-epithelial cells, selective targeting of agents to re-
activate Ocln expression should improve the safety to efficacy profile for the drugs 
being identified. Pancreatic cancer cells, commonly activated by the 
Ras/Raf/MEK/ERK pathway, strikingly up-regulate the nutrient di/tri-peptide import 
protein hPepT1 (19). Up-regulated hPepT1 has also been observed on pancreatic, 
prostatic, and gastric cancer cells and its function appears to be important for cell 
survival (20, 21), suggesting a critical role for hPepT1 expression in these cancer cells. 
Previous studies have demonstrated that small molecule can be made into hPepT1 
substrates by chemical coupling to certain amino acids (22-24), suggesting that a 
variety of molecules identified in our studies might be made into a selective hPepT1 
substrate.  
Based upon the approach outlined above, we have examined two separate screening 
strategies to identify agents capable of re-activating OCLN expression and which might 
be made into hPepT1-selective substrates. One strategy used a phage display strategy 
to identify small peptides capable of disrupting Slug binding to the OCLN promoter. 
The other strategy was cell-based, using a cancer cell line stably expressing a reporter 
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gene constructed from the open reading frame of luciferase and the OCLN promoter. 
Together, these screening strategies have provided an initial assessment for the 
feasibility of our approach to identify reversible EMT↔MET process that can be 
regulated in-synch with agents that affect these processes and which could be 
selectively targeted based upon concurrent cellular modifications.  
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MATERIALS AND METHODS 
Phage display  
DNA and construction of genes.  
Oligoduplexes used in affinity selection of phage-displayed peptides and in the Slug 
protein binding assays were an occludin (OCLN) gene promoter fragment containing E-
box motif that is underlined. The Oligoduplexes were obtained by annealing the 
following oligonucleotide pairs: OCLN sense, 5’-catccgagtttcaggtgaattggtcaccg-3 and 
antisense, 5’-cggtgaccaattcacctgaaactcggatg-3; OCLN mutant, sense, 5’-
catccgagtttcttcagaattggtcaccg-3 and antisense, 5’-cggtgaccaattctgaagaaactcggatg-3. 
The annealing reaction was carried out in a buffer (10 mM Tris-HCl, pH 7.4, 50 mM 
NaCl) at 94 oC for 5 min and then at room temperature for 40 min. Both biotinylated 
and non-biotinylated oligos were prepared.  
A plasmid containing human slug gene was amplified by PCR using primers (sense, 5’-
gcggatccccgcgctccttcctggtcaag-3’ and antisense, 5’-ggaattcttagtgtgctacacagcagcc -3’), 
and subcloned into the BamHI/EcoRI site of pProEX HTb (InVitrogen). The resulted 
plasmid, denoted pSlug, was fused to green fluorescence protein (gfp) (Clontech) at 
the N-terminus of slug. gfp was amplified by PCR using primers (sense, 5’-
gggatccatcgccaccatggtgagc-3’ and antisense, 5’-gggatcccttgtacagctcgtccatgc-3’), and 
subcloned into the BamHI site of pSlug. The resulted plasmid was termed pgfpSlug. 
Plasmid constructs containing Renilla luciferase (Rluc) reporter gene under the 
regulation of human occludin promoter were generated by a multistep process. 
Briefly, a full-length human OCLN promoter genomic DNA (1853 bp fragment 
containing -1511 to +342 bp from the transcription start site) was generated by PCR 
using primers (sense, 5”-cgtcgcgaattatgctaagtgaaagaagacag-3’ and antisense, 5’-
gcggatccgcgctctggacctggctggctctcgg) and OCLN/pGL3 (17) as a template. The PCR 
products were cut by NruI and BamHI and cloned into the NruI-BamHI site of 
pcDNA3.1(+) (Invitrogen). Insertion of this OCLN promoter DNA fragment resulted in 
the deletion of the CMV promoter region in the vector. Rluc gene (Promega) was 
generated by PCR using primers (sense, 5’-gcggatccgcaccatgacttcgaaagtttatgatcc-3’ 
and antisense, 5’-gatctagagttattgttcatttttgagaactcgctcaacg-3’). The amplified R. luc 
gene fragment was cut by BamHI and cloned into the BamHI site of pCDNA3.1(+) in 
which the CMV promoter has been replaced by OCLN promoter. The resulted plasmids 
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were named as pOccRluc. A negative control construct (pRluc) containing Rluc under 
the control of CMV promoter was also made. All resulting constructs were verified by 
restriction enzyme digestions and DNA sequencing. 
Protein expression and purification.  
E.coli BL21 DE3 cells (Stratagene) were transformed with pgfpSlug. Protein expression 
was induced by addition of 1 mM isopropyl-D-thiogalactopyranoside (IPTG) when the 
culture OD600 reached 0.8.Three hours following IPTG induction, cells were harvested 
by centrifugation (4000 rpm for 15 min at 4 oC). The cell pellet was re-suspended in 30 
ml of cold lysis buffer (20 mM Tris-HCl, pH 8.0, 20% glycerol, 0.5 M NaCl, 1 mM TCEP, 
one EDTA-free protease inhibitor tablet). The cell suspension was sonicated on ice, 
combined with NP-40 (final concentration of 1%) and rocked for 30 min at 4 oC. The 
lysate was centrifuged at 14,000 rpm at 4oC for 30 min. The supernatant was 
incubated with 1 ml of pre-equilibrated (lysis buffer +NP-40) Ni-NTA agarose beads 
(Qiagen) for 2 hours at 4 oC with gentle rocking. The suspension was then spun at 2000 
rpm and pelleted beads were washed 5 times with 10 ml of cold wash buffer (20 mM 
Tris-HCl, pH 8.0, 20% glycerol, 0.5 M NaCl, 1 mM TCEP, 15 mM imidazole). Resins were 
transferred to a poly-prep column (BioRad) and protein was eluted with 5 bed volumes 
of elution buffer (20 mM Tris-HCl, pH 8.0, 10% glycerol, 0.1 M NaCl, 1 mM TCEP, 250 
mM imidazole). The purified protein was analyzed by SDS-PAGE and Western blot.  
Assaying for Slug protein binding to E-box DNA.  
The procedure for assaying Slug binding to E-box DNA is shown in Figure 1. Briefly, DNA 
oligoduplexes used in affinity selection of phage-displayed peptides and in Slug binding 
assays were annealed as described above. 96-well plates were coated with 
streptavidin (10 μg/ml, 100 μL/well) at 4 oC overnight. The plates were washed three 
times with washing buffer (PBS, 0.05% Tween-20), and blocked with blocking buffer 
(PBS, 0.05% Tween-20, 5% milk). Eight μg of Slug fusion protein was incubated 
together with 1 μM of biotinylated or unbiotinylated DNA ligands in binding buffer (10 
mM Tris-HCl, pH 7.4, 50 mM NaCl, 5% glycerol, 1 mM EDTA, 4 mM DTT) on ice for 30 
min in a volume of 200 μL. The mixtures were transferred into plates coated with 
strepavidin, and incubated at room temperature for 1 h. Captured Slug-DNA complexes 
were washed 3 times (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-20),  and 
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detected using a microplate reader (BioTek) for fluorescence, or with HRP-conjugated 
anti-GFP antibody for luminescence.  
Generation of stable cell lines.  
The pOccRluc and control constructs pRluc and pcDNA3.1 were transfected into human 
non-small lung carcinoma cell line H460 and cervix adenocarcinoma cell line Hela 
(ATCC) using transfection reagent Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. Stable cell lines were selected in 500 μg/mL hygromycin, 
validated for the integration of the chimeric gene into the cell genome by genomic 
PCR, and maintained in DMEM medium supplemented with 300 μg/mL hygromycin. 
Integration of plasmid pOccRluc was further functionally verified by treating the cells 
with MEK inhibitor PD98059 which resulted in increased luciferase expression using a 
commercial kit (Promega).  
Compound screening protocols.  
Cell-based reporter screening system. H460-pOccRluc, along with positive control 
H460-pRluc, and negative control H460-pcDNA3.1 cells were seeded at 8000 cells/well 
in 100 μL DMEM complete medium in 96-well white with clear bottom plates. Plates 
were made up in triplicate, seeded on day 1, treated on day 2 with test compounds, 
and assayed on day 4. Test compounds were tested at 5 μM, being added in DMSO 
(final concentration of 0.4%); with control wells receiving an equivalent amount of 
DMSO. The addition of DMSO to some wells was also used to serve as a negative 
control. After 48 hr of test compound exposure, the medium was aspirated, and cells 
were lysed with 30 μL/well fresh-prepared lysis buffer (150 mM HEPES,  pH 8.0, 0.05% 
Triton X-100, 1 mg/ml Porcine Gelatin, pH 7.6, 10% Glycerol)  at room temperature for 
10 min with shaking. 30 μL of 1X Renilla luciferase assay substrate working solution 
(0.01 mg/ml Renilla luciferase assay substrate Coelenterazine, 5M NaCl, 0.5M KH2PO4, 
0.1M EDTA, pH 8.0, 1mg/ml Porcine Gelatin, pH7.6) was then added to each well and 
luminescence was read immediately using a luminometer (BioTek).    
Protein-based screening system. Test compounds were first incubated in binding 
solution with E-box DNA or control biotin-labeled oligoduplexes. After addition to 
steptavidin-coated plates, these oligoduplexes were exposed to eight ug of GFP-Slug. 
After washing with washing buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween-
20), the presence of materials capable of competing for the Slug binding site on the 
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occludin promoter E-box was monitored  by the lack of or reduced fluorescent signal 
for bound GFP-Slug using a fluorimeter. Biotin-labeled E-box oligoduplexes without 
test compounds served as a positive control, while a mutant E-box sequence lacking 
the ability to bind Slug (17) and non-biotinylated E-box oligoduplex served as negative 
controls.  
Phage display. Two phage display peptide libraries, Ph.D.-7 and -12 (New England 
Biolabs), were used to generate random 7-mer or 12-mer peptide sequences in the N-
terminal of pVIII coat protein of M13 phage. The phage selection procedure, based on 
affinity purification, was performed as described in the manufacturer’s manual and 
with modifications (25, 26). The target, 1 μM biotin-labeled occludin promoter E-box 
oligoduplex, was incubated with 2x1011 phage in a TBST solution (50 mM Tris-HCl 
pH7.5, 150 mM NaCl, 0.1% (v/v) Tween-20) in a final volume of 400 μL for 1 h at room 
temperature. Phage/DNA mixtures were then added to 100 μL of 1 mg of streptavidin-
coated paramagnetic beads (Dynabeads M-280 streptavidin, Invitrogen) previously 
washed three times in 500 μL of TBST and incubated for additional 30 min before the 
beads were collected and washed five times with 500 μL of ice-cold TBST. In the last 
wash, beads were transferred to a clean tube and eluted with 100 ul of elution buffer 
(0.2 M Glycine-HCl, pH 2.2, 1 mg/ml BSA) for 10 min and neutralised with 15 μL of 1M 
Tris-HCl (pH 9.1). An aliquot (1 ul) of eluted phage was used for micro-titration, with 
the remaining phage being amplified for next rounds of bio-panning. The selection 
procedure was repeated for two additional rounds. In the first round, binding and 
washing reactions were in TBS with 0.1% (v/v) Tween-20, but in the second and third 
rounds TBS with 0.5% Tween-20 were used. Single-stranded DNA was then prepared to 
detect consensus binding sequences.  
Validation of selected peptide phages for target binding by ELISA. One clone from 
each group of identified target binding peptides containing a consensus sequence was 
selected and assayed for DNA target binding by ELISA. Briefly, the phage-containing 
supernatants, saved when carrying out the plaque amplification for DNA sequencing, 
were amplified and purified. Biotinylated E-box DNA was incubated with the phage in 
solution. The mixtures were transferred into a streptavidin-coated ELISA plate. Bound 
phage-DNA complexes were detected with HRP-conjugated anti-M13 antibody 
(Pharmacia) and a microplate reader set at 410 nm. 
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Assay of selected peptides for competitive inhibition of Slug binding to E-box DNA.  
After the validation of selected peptide phages for target binding by ELISA, identified 
E-box-binding peptide variants were synthesized by American Peptide Co., and  tested 
for their ability to compete with Slug for binding to the E-box DNA. Specifically, 
biotinylated E-box DNA, each peptide to be characterized, and Slug protein were 
incubated in binding buffer on ice for 30 min. The mixtures were transferred into 
plates coated with strepavidin and incubated at room temperature for 1 h. The 
captured peptide-DNA or Slug-DNA complexes were washed 3 times and detected as 
described above.  In another experiment, Slug and E-box DNA were first incubated on 
ice for 30 min, the testing peptides were added, and then the ability of the peptides 
to remove Slug from the E-box DNA was determined as described above.  
 
HYPOTHESIS AND RATIONALE OF STUDIES 
Hypothesis behind strategy to find agents to rectify cell-cell contacts. Normal 
epithelia undergo dynamic changes that involve transient periods of de-differentiation 
that allows for mitosis and cell migration followed by differentiation to re-establish 
functional barriers (Fig 1A). Such events are essential for development, wound repair, 
and replacement of senescent cells. Our hypothesis centers on the idea that epithelial 
cancer cells have entered into the de-differentiation pathway but have lost the ability 
to re-establish functional barriers required for re-establishment of a differentiated 
phenotype (Fig 1B). A variety of factors could block the re-establishment of functional 
barriers that drive differentiation (27). We have focused on identifying ways to reverse 
EMT events with the outcome of potentially overcoming drug resistance to various 
anti-cancer agents (28) or making cancer cells significantly more susceptible to these 
agents. 
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A)       B) 
                     
Figure 1. Hypothesis for epithelial oncogenesis based upon an inability to reverse 
genotypic and phenotypic events driving epithelial to mesenchymal transformation 
(EMT).  A) Normal sequence of events at an epithelium where lesions or senescence 
leads to a loss of differentiated epithelial cells resulting in compromised barrier 
function. Note the role of growth factors to drive cell division of un-differentiated 
cells prior to their re-differentiation following the establishment of functional cell-cell 
contacts. B) In the presence of constitutive growth drivers (or lack of growth 
suppressors), epithelial cells fail to re-differentiate and continue to grow, possibly 
with the capability to migrate to distant sites in the body following a breach of the 
basement membrane. Tight junction complexes (red box); Basement membrane (solid 
black bar); Basement membrane penetrated by oncogenic epithelial cells (hatched 
black bar).  
 
In the present studies we have focused on the mechanism used by active raf to down-
regulation of tight junction (TJ) structures, with particular attention on the TJ protein 
Ocln which appears to have orchestrating capability in the formation of nascent TJs 
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(10). Using an epithelial cell model, we have determined that activation of the 
Ras/Raf/MEK/ERK pathway results in an increase in function of the repressor protein 
Slug which directly blocks OCLN transcription to maintain epithelial cells in a de-
differentiated form (17). As a result of this de-differentiation, epithelial cells should 
express a distinct set of surface elements, some of which might be used to target pro-
drug agents to these non-polarized cells following systemic administration. We had 
examined potential uptake mechanisms in pancreatic cancer cell lines with the intent 
of identifying such an uptake mechanism and made the observation that a low-affinity, 
high-capacity, poorly-selective uptake protein, known as PepT1, was over-expressed 
on these cells (19). Thus, a rationale exists to search for either small peptide-like 
agents that might enter cancer cells through PepT1 and block slug-mediated 
suppression of the OCLN promoter or for small molecules that could re-activate OCLN 
expression. Once reaching epithelial cancer cells, the agent would induce functional 
TJ structures to be re-established, leading to suppression of cancer cell growth and 
potentially an increased susceptibility to chemotherapeutic agents (Fig. 2).   
 
 
Figure 2. Conceptual cartoon depicting how disorganization of tight junction function 
leads to oncogenic conversion and how restitution of function tight junctions through 
the orchestrating actions of occludin (Ocln) can lead to rectification of differentiated 
epithelial cells. 
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RESULTS 
Activity of hPepT1 required for functional targeting. While hPepT1 is strikingly up-
regulated at the protein level in pancreatic cancer cell lines (19), we wished to better 
understand the nature of hPepT1 function in response to Ras/Raf/MEK/ERK pathway 
activation. We used a non-cancerous rat salivary gland epithelial (Pa4) cells induced to 
undergo EMT by the introduction of constitutively active Raf (Pa4-Raf1) that were then 
induced to revert through MET program following in the forced expression of Ocln 
(Pa4-Raf1-Ocln) as previously described (10). We compared the gene expression 
profiles of Pa4, Pa4-Raf1, and Pa4-raf1-Ocln cells using a commercial array from 
Paradigm Genetics Inc (Research Triangle Park, NC), focusing on PepT1 and elements 
known to regulate its function. Although PepT1 was not significantly altered in this 
array comparison (data not shown), two genes known to regulate Pept1 function were 
tightly regulated in the Raf/Ocln dynamic: Slc9a5 and Prkaa2. Scl9a5 is an isoform of 
the Na+/H+-exchanger whose activity is critical to maintain the proton gradient 
required for optimal Pept1 function (29). The mRNA level of Scl9a5 was observed to 
increase 1.5-fold following EMT induced by constitutively active Raf1 (Pa4→Pa4-Raf1) 
and to decrease in a comparable fashion (1.7-fold) in Raf1-active cells following the 
forced expression of Ocln Pa4-Raf1→Pa4-Raf-1-Ocln). Prkaa2 is an AMP-activated 
protein kinase that suppresses the activity of hPept1 (22). The mRNA level of Prkaa2 
decreased 2.1-fold following EMT induced by constitutively active Raf1 and increased 
2.7-fold in Raf1-active cells following in the forced expression of Ocln. Together, 
these results suggest that cellular processes that control hPepT1 activity are 
positioned to ensure its increased activity following EMT driven by Ras/Raf/MEK/ERK 
pathway activation and more tightly regulated function when expressed in 
differentiated epithelial cells.  
Validation of Slug-E-box Binding Assay. A method to monitor Slug binding to the E-
box domain promoter region of OCLN was validated through a series of positive and 
negative control studies (Table 1). As a positive control, biotin-labeled E-box 
oligoduplex of OCLN promoter DNA was incubated with a Slug-green fluorescent 
proteins (GFP) protein chimera (Fig. 3). Complexes formed in solution were captured 
on surfaces conjugated with streptavidin and detected using a horseradish peroxidase 
(HRP) conjugated antibody that recognized GFP; a signal that could be reduced by the 
inclusion of an equal amount of E-box DNA lacking biotin (Table 1). In addition, assay 
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output signals were independent of addition sequence for biotin-labeled or unlabeled 
forms of OCLN E-box DNA when mixing with Slug-GFP, suggesting that the interaction 
between OCLN E-box DNA and Slug is dynamic and thus reversible (data not shown). To 
verify specificity, Slug-GFP was incubated with two different mutant forms of biotin-
labeled occludin E-box oligos (Table 1). For a constant amount of OCLN E-box 
sequence DNA, Slug-GFP bound in a dose-dependent manner; saturated binding 
occurred at ~8 μg, a ratio that was used in all subsequent studies (Table 2).  
Table 1. Validation of specificity for Slug interaction with human OCLN E-box.  
 
Treatment Slug 
only 
E-Box 
only 
Slug  + 
E-Box 
Slug + E-Box 
mutant 1 
Slug + E-Box 
mutant 2 
Slug  + 
E-Box* 
Slug + E Box 
+E-Box* 
Luminescence 4 0 340 4 7 3 145 
 
E-box:                Biotin-catccgagtttcaggtgaattggtcaccg  
E-box*:                              -catccgagtttcaggtgaattggtcaccg  
E-box mutant 1:    Biotin-catccgagtttcttcagaattggtcaccg  
E-box mutant 2:    Biotin-catccgagtttaaggtaaattggtcaccg  
 
Table 2. Slug-GFP binds to the OCLN E-box in a dose-dependent manner.   
 
Slug (μg/well) 0.1 0.2 0.4 0.8 1 2 4 6 8 10 15 20 
Luminescence 45 45 90 130 145 200 240 265 280 280 290 260 
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Figure 3. Diagram of screening method to identify molecules and short peptides 
capable of blocking interactions between Slug and the E-box region of the promoter 
region of OCLN. The gene for human Slug was genetically fused to green fluorescent 
protein (GFP) and the resulting chimera was used in a 96-well plate format to evaluate 
small molecules or short peptides identified through panning with phage that 
displayed random formats of either 7 or 12 amino acid peptide sequences.  
 
Phage panning with OCLN E-box DNA. Ph.D.-7 and Ph.D.-12 phage peptide libraries 
were panned using biotin-labeled OCLN E-box DNA (Table 1). Three rounds of panning 
were carried out in each screen with the Ph.D.-12 library being screened once and the 
Ph.D.-7 library being screened twice. Subtraction for E-box specificity was performed 
by a binding step using biotin-labeled DNA sequence containing a mutant E-box 
sequence shown not to interact with Slug (17). Ten individual phages from the third 
round of each panning were propagated with DNA encoding the insert in the fusion 
protein (pVIII) being sequenced and translated into amino acid sequences (Table 3). 
There were significant variations in the amino acid sequences that selectively bound 
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to OCLN E-box DNA, although some sequences were enriched with a frequency as high 
as 30%. Closer inspection, however, was used to identify short peptide sequences of 2-
5 amino acids that repeated within the 7- or 12- amino acid phage libraries as well as 
between these libraries. These similarities are highlighted with underlining (Table 3).  
Table 3. Peptide sequences identified through Phage panning that bind to the OCLN E-
box sequence.   
 
Library Peptide sequence Frequency 
Ph.D.-7  YSLRLDY         0.25 
 KCCFPIS  0.15 
 KCCFINA 0.1 
 KCCYVPL  0.1 
 KCCYATH  0.05 
 QAPTRVQ 0.05 
 APTAVSK 0.05 
 KVWQIVT  0.05 
 KVWLLPP  0.05 
 RPPVFHM  0.05 
 NKTIMAL 0.05 
 IPKHTYR 0.05 
Ph.D.-12 KHTFIDYLVSQA 0.3 
 FNDRPVLSYMNL 0.1 
 KCCFHSTENPHP 0.1 
 HMDYYNWRRLSL 0.1 
 LRSKIRIPLNRR 0.1 
 
By combining data from the Ph.D-7 and -12 phage studies, the sequence (Iso/Leu)-Asp-
Tyr was found to be present in 55% of all the phage sequenced. Further examination of 
the Ph.D-12 phage studies suggested that this sequence could be extended with a 
preceding phenylalanine and a following valine: Phe-(Iso/Leu)-Asp-Tyr-X-Val. Another 
sequence observed in both the Ph.D.-7 and -12 phage panning was Lys-Cys-Cys-
(Phe/Tyr) which occurred with an overall frequency of 50% (Table 3). Other amino 
acids sequences repeated within sequences phage were Arg-Arg (20%), Ala-Pro-Thr-X-
Val (10%), Lys-Val-Trp (10%), and Pro-Pro (10%). Together, this data set is consistent 
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with the idea that a defined set of structures exists within the OCLN E-box DNA that 
can be selectively targeted through distinct peptide sequences.  
Inhibition of Slug binding to E-box oligoduplex. To determine whether peptides 
selected by phage display outcomes could inhibit Slug binding to the OCLN E-box, 
three peptides with the sequences Thr-Phe-Iso-Asp-Tyr-Pro-Val-Leu-Ser (TFIDYPVLS), 
Lys-Cys-Cys-Phe-Pro-Iso-Ser-Thr-Glu (KCCFPISTE), and Gln-Pro-Pro-Thr-Val-Ser-Val-Ser-
Lys (QPPTVSVSK) were synthesized (Table 3). The peptide Iso-Glu-Asp-Gly-Ser-Val-Gly-
Leu-Ala (IEDGSVGLA) was used as a negative control (Fig. 3). About 65% of Slug binding 
to target DNA was blocked by TFIDYPVLS or KCCFPISTE but only a 42 % reduction in 
Slug binding resulted in the presence of QPPTVSVSK (Fig. 3). Interestingly, others 
peptides synthesized that emulated the zinc finger domains of Slug {Stegmann, 1999 
#60} only reduced GPF-Slug binding by ~30% (data not shown). 
Identification of Ocln re-activating molecules. Additional agents capable of re-
activating Ocln expression were identified using cancer cells modified to contain a 
chimeric gene composed of the Ocln promoter and the luciferase open reading frame. 
De-repression of the Ocln promoter suppressed by active Ras/Raf/MEK/ERK function in 
these cells resulted in luciferase-induced light as a high-throughput screening (HTS) 
readout. This HTS method was use to screen a chemical library obtained from the 
National Cancer Institute (NCI). After two screening rounds, 15 hits were identified. 
These hits included the compounds PD98059, U0126, and Triciribine. Both PD98059 
and UO126 inhibit MEK1 and MEK2 kinases to represses anchorage-independent growth 
(30). Triciribine, an Akt kinase inhibitor, can induce apoptosis and inhibit cell growth 
(31). De-repression of OCLN promoter function by these kinase inhibitors functioned as 
positive controls, validating the HTS protocol used. Increased Ocln protein levels, 
corresponding to increased luciferase activity, were confirmed by Western blotting for 
all hits (data not shown).  
Identification of Ocln re-activating molecules. A number of compounds identified 
from the NCI chemical library were effective at 10 μM with the ability to out-perform 
the positive control of 20 μM PD98059 for luciferase induction. These compounds 
induced Ocln expression, a MET morphology change, and growth suppression (Table 4). 
Several other compounds were identified in the screen out-performed 20 μM PD98059 
when tested at 100 μM but failed to have an effect when tested at 10 μM. Another 
cadre of molecules induced MET morphology change and growth suppression without 
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producing an effect on luciferase expression greater than that observed for PD98059. 
This screening approach was unbiased toward mechanism of action. Most compounds 
identified at hits had the ability to induce morphology changes consistent with MET 
and growth suppression which correlated well with re-activation OCLN promoter 
function. A few molecules with growth suppressive function did not correlate with 
OCLN activation; this group of compounds was not pursued further.   
Table 4. High throughput screening hits. Compound code name, molecular formula, 
molecular weight, and compound structure information were provided by the library 
source: the National Cancer Institute. Hits listed out-performed the MEK inhibitor 
PD98059 at 20 μM for induction of luciferase expression. Morphology change consistent 
with MET, and extent of growth suppression are listed. 
 
Code Name     
Mol. Formula   
Mol. Weight 
Compound Structure MET; Growth 
inhibition at 
effective conc.   
42846-F    
C13H15N3            
213 Da  
 
Yes                        
~ 40% at 10 μM 
23583-Q 
C19H24N8O4           
428 Da 
 
Yes                        
~ 60% at 10 μM 
133488-F 
C15H11N3O5S 
345 Da  
 
ND             
Effective  at 10 μM 
102728-T 
C20H19NO2   
342 Da 
 
ND             
Effective  at 10 μM 
40384-C 
C6H6N2O4    
170 Da 
 
Yes                        
~ 45% at 100 μM 
61735-L 
C9H8O5       
196 Da  
Yes                        
~ 40% at 100 μM 
27895-C 
C10H12N2O2 
192 Da 
 
Yes                        
~ 55% at 100 μM 
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403734-Y 
C3H6N2O2S 
134 Da  
Yes                        
~ 55% at 100 μM 
30154-J 
C9H15N3          
165 Da 
 
Yes                        
~ 55% at 100 μM 
 
 
Examination of hits identified from the NCI chemical library led to the recognition of a 
few recurring structural elements. Compounds capable of affecting MET and cancer 
cell growth at 10 μM contained several aromatic ring moieties that were modified by 
either methyl or carboxyl groups. Interestingly, compounds that failed to affect MET 
and cancer cell growth at 10 μM but did so when tested at 100 μM were smaller, 
simpler compounds than the first group. Except in one case, these smaller, less active 
compounds also contained an aromatic structure and either a methyl and carboxyl 
group.  Importantly, the size and nature of compounds identified in this screen were 
amenable for modification to become selective substrates for hPepT1.  
 
DISCUSSION 
Herein we describe the rationale behind a novel approach to improve the selectivity 
and targeting of molecules that could induce an MET event in epithelial cancer cells 
and take initial steps toward the validation of that approach.  In some ways, this 
approach is similar to that proposed by others who have examined genes associated 
with EMT events as a strategy to identify possible therapeutic targets for treating 
ductal pancreatic adenocarcinoma (28). Our strategy extends previous approaches by 
taking advantage of two important observations: MET events driven by 
Ras/Raf/MEK/ERK pathway activation can be reversed by the expression of the TJ 
protein Ocln (10) and pancreatic epithelial cancer cells can up-regulate expression of 
the nutrient di/tri-peptide import protein hPepT1 (19). At the intersection of these 
observations rests the idea that compounds resembling hPepT1 substrates could be 
selectively taken up by this transporter over-expressed on certain types of epithelial 
cancer cells. In the present studies, we have presented evidence suggesting that 
hPepT1 is not only up-regulated at the protein level but that the cellular conditions 
following EMT provide an environment for increased functional expression of this 
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uptake pathway. Further, we describe strategies to identify compounds which might 
specifically affect EMT↔MET events by re-activating Ocln expression suppressed due 
to the activation of the Ras/Raf/MEK/ERK pathway and which could directly or be 
modified to function as hPepT1 substrates.  
Two types of screens were established to identify Ocln re-activating molecules; both 
were based upon recent findings that defined the mechanism used by cells to suppress 
Ocln expression following Ras/Raf/MEK/ERK pathway activation.  One screening 
format was based upon selectively disrupting the interaction between Slug and the E-
box motif of the OCLN promoter. Phage panning was used to identify short peptide 
sequences capable of inhibiting Slug/E-box motif interactions and the ability of 
peptides identified in this way were verified to block Slug binding to the E-box motif 
of the OCLN promoter. In this next stage of this program, minimal peptide structures 
that retain the ability to block Slug/E-box motif interactions will be identified through 
a rational design approach based upon these peptide sequences identified in this 
screen.  
A second screen employed a Raf1-driven epithelial cell with an inserted reporter 
chimera gene that allowed for the expression of luminescence signal following re-
activation of OCLN promoter function. Not being focused to a particular element of 
the dynamic established between the Ras/Raf/MEK/ERK pathway and the Ocln 
protein, this screen led to the identification of compounds from a chemical library 
whose mechanism of action would be unknown. The unbiased outcomes from this 
screen could be grouped into two categories: those that affected MET and cancer cell 
growth at 10 μM and those that produced these same outcomes but only at higher 
concentrations, in this case 100 μM. Subsequent studies will involve making a series of 
modifications to these hits to indentify critical elements for function in order to 
develop potential lead candidates.  
Overall, these studies have described not only a strategy to identify a novel class of 
anti-cancer agents but provided in vitro evidence that cancer cells can be affected by 
molecules identified through these screening strategies. These screens were 
performed with the intent of identifying hits that could be developed into potential 
lead candidates. To identify these leads, we will combine information obtained from 
peptide sequences capable of blocking Slug binding to the OCLN promoter E-box with 
that of small molecule compounds identified from an NCI chemical library. The 
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approach described represents a unique strategy where a selective uptake pathway 
up-regulated in cancer cells driven by a particular oncogene pathway is integrated into 
the lead development as a means of targeting the delivery of compounds that 
functionally block an MET suppression system. In this case, we have used the specific 
relationship between the Ras/Raf/MEK/ERK pathway and the TJ protein Ocln to allow 
for the selective targeting and reversal of EMT processes. Once cells revert via MET 
phenotype changes, we believe they may 1) stop growing aggressively with a reduced 
potential for metastasis (1, 14), and 2) be more susceptible to stress agents currently 
being tested as chemotherapeutics. The dynamic used in our studies should be useful 
to treat epithelial cancers derived from the pancreas, stomach, and prostate where 
up-regulation of the Ras/Raf/MEK/ERK pathway can be confirmed.  It is possible that 
other cancer cells may be similarly targeted and treated via other dynamics 
established to control EMT↔MET events, such as those involving the 
PI3K/PTEN/Akt/mTOR pathway (6, 31).  
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TABLES 
Table 1. Validation of specificity for Slug interaction with human OCLN E-box.  
 
Treatment Slug 
only 
E-Box 
only 
Slug  + 
E-Box 
Slug + E-Box 
mutant 1 
Slug + E-Box 
mutant 2 
Slug  + 
E-Box* 
Slug + E Box 
+E-Box* 
Luminescence 4 0 340 4 7 3 145 
 
E-box:                Biotin-catccgagtttcaggtgaattggtcaccg  
E-box*:                              -catccgagtttcaggtgaattggtcaccg  
E-box mutant 1:    Biotin-catccgagtttcttcagaattggtcaccg  
E-box mutant 2:    Biotin-catccgagtttaaggtaaattggtcaccg  
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Table 2. Slug-GFP binds to the OCLN E-box in a dose-dependent manner.   
 
Slug (μg/well) 0.1 0.2 0.4 0.8 1 2 4 6 8 10 15 20 
Luminescence 45 45 90 130 145 200 240 265 280 280 290 260 
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Table 3. Peptide sequences identified through Phage panning that bind to the OCLN E-
box sequence.   
 
Library Peptide sequence Frequency 
Ph.D.-7  YSLRLDY         0.25 
 KCCFPIS  0.15 
 KCCFINA 0.1 
 KCCYVPL  0.1 
 KCCYATH  0.05 
 QAPTRVQ 0.05 
 APTAVSK 0.05 
 KVWQIVT  0.05 
 KVWLLPP  0.05 
 RPPVFHM  0.05 
 NKTIMAL 0.05 
 IPKHTYR 0.05 
Ph.D.-12 KHTFIDYLVSQA 0.3 
 FNDRPVLSYMNL 0.1 
 KCCFHSTENPHP 0.1 
 HMDYYNWRRLSL 0.1 
 LRSKIRIPLNRR 0.1 
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Table 4. High throughput screening hits. Compound code name, molecular formula, 
molecular weight, and compound structure information were provided by the library 
source: the National Cancer Institute. Hits listed out-performed the MEK inhibitor 
PD98059 at 20 μM for induction of luciferase expression. Morphology change consistent 
with MET, and extent of growth suppression are listed. 
 
Code Name     
Mol. Formula   
Mol. Weight 
Compound Structure MET; Growth 
inhibition at 
effective conc.   
42846-F    
C13H15N3            
213 Da  
 
Yes                        
~ 40% at 10 μM 
23583-Q 
C19H24N8O4           
428 Da 
 
Yes                        
~ 60% at 10 μM 
133488-F 
C15H11N3O5S 
345 Da  
 
ND             
Effective  at 10 μM 
102728-T 
C20H19NO2   
342 Da 
 
ND             
Effective  at 10 μM 
40384-C 
C6H6N2O4    
170 Da 
 
Yes                        
~ 45% at 100 μM 
61735-L 
C9H8O5       
196 Da  
Yes                        
~ 40% at 100 μM 
27895-C 
C10H12N2O2 
192 Da 
 
Yes                        
~ 55% at 100 μM 
403734-Y 
C3H6N2O2S 
134 Da  
Yes                        
~ 55% at 100 μM 
30154-J 
C9H15N3          
165 Da 
 
Yes                        
~ 55% at 100 μM 
 
